Key Takeaways Insulet shares tumbled Friday after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024. Strong sales of its Omnipod device helped Insulet top second-quarter revenue expectations. The company raised its guidance for full-year revenue growth. Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth cou ...

Insulet Corporation (PODD) reported second-quarter 2024 adjusted earnings per share (EPS) of 55 cents, up significantly 44.7% from the year-ago period's figure. The bottom line missed the Zacks Consensus Estimate by 3.5%. GAAP EPS was $2.59 compared with the year-ago figure of 39 cents. Q2 Revenues Revenues totaled $488.5 million, which beat the Zacks Consensus Estimate by 5.5%. The top line jumped 23.2% year over year (up 23.4% at the constant exchange rate or CER). CER growth exceeded the company's guidan ...

| --- | --- | --- | --- | --- | |------------------|-------|-------------------|-------|-------| | | | | | | | | | Mattie | | | | | | Podder since 2010 | | | | | | | | | | | | | | | | Insulet | | | | | | Corporation | | | | | | Q2'24 Earnings | | | | | | August 8, 2024 | | | | | This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulat ...

Insulet Corporation (NASDAQ:PODD) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Maria Chadwick - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Travis Steed - Bank of America Michael Polark - Wolfe Research Matt Taylor - Jeffe ...

Insulet (PODD) reported $488.5 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 23.2%. EPS of $0.55 for the same period compares to $0.38 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $463.13 million, representing a surprise of +5.48%. The company delivered an EPS surprise of -3.51%, with the consensus EPS estimate being $0.57. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -3.51%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.39 per share when it actually produced earnings of $0.73, delivering a surprise of 87.18%. Over the last four qua ...

Table of Contents _____________________________________________________ ________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q _____________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE ...

Exhibit 99.1 Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue, Gross Margin and Operating Margin Guidance ACTON, Mass. - August 8, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended June 30, 2024. ® Second Quarter Financial Highlights: 1 • Second quarter 2024 revenue of $488.5 million, up 23 ...

Insulet (PODD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Therefore, the Zacks rating upgrade for Insulet basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade f ...

Timothy Scannell, former President and Chief Operating Officer of Stryker Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating h ...